[Combination of trimethoprim and sulfamethoxazole in coliform urinary infections].
D000704:Analysis of Variance; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D005493:Folic Acid Antagonists; D011743:Pyrimidines; D014295:Trimethoprim; D013420:Sulfamethoxazole
Association triméthoprim-sulfaméthoxazole dans l'infection urinaire à coliformes.